Compositions and methods for treating cancer with DuoCARs
Rimas J. Orentas, Seattle, WA (US); Dina Schneider, Potomac, MD (US); Waleed M. Haso, Santa Monica, CA (US); Stefan Miltenyi, Bergisch Gladbach (DE); and Boro Dropulic, Ellicott City, MD (US)
Assigned to LENTIGEN TECHNOLOGY, INC., Gaithersburg, MD (US)
Filed by Lentigen Technology, Inc., Gaithersburg, MD (US)
Filed on Dec. 2, 2021, as Appl. No. 17/540,377.
Application 17/540,377 is a continuation of application No. 16/692,957, filed on Nov. 22, 2019, granted, now 11,208,455.
Application 16/692,957 is a continuation in part of application No. PCT/US2019/051734, filed on Sep. 18, 2019.
Application PCT/US2019/051734 is a continuation of application No. 16/134,735, filed on Sep. 18, 2018, granted, now 10,689,431, issued on Jun. 23, 2020.
Application 16/134,735 is a continuation in part of application No. 16/078,269, granted, now 11,453,712, previously published as PCT/US2017/049923, filed on Sep. 1, 2017.
Claims priority of provisional application 62/382,791, filed on Sep. 2, 2016.
Prior Publication US 2022/0169698 A1, Jun. 2, 2022
3. A pharmaceutical composition comprising an antitumor effective amount of a population of isolated human lymphocyte cells, wherein the cells of the population include cells comprising (a) nucleic acid molecules encoding at least one multicistronic vector; (b) wherein the at least one multicistronic vector comprises a promoter operably linked to a multicistronic nucleic acid sequence encoding two or more functional CARs comprising an extracellular antigen binding domain, a transmembrane domain, one or more non-identical intracellular signaling motifs, wherein each of the encoded two or more functional CARs comprises a non-identical amino acid sequence that is independently selected from the group consisting of the amino acid sequence of SEQ ID NO: 110, 112, 114, and 116, wherein the at least one multicistronic vector is used to genetically modify the population of human lymphocyte cells.